Literature DB >> 11274084

Substance P and vasoactive intestinal polypeptide in the streptozotocin-induced diabetic rat retina.

J Troger1, S Neyer, C Heufler, H Huemer, E Schmid, U Griesser, M Kralinger, B Kremser, I Baldissera, G Kieselbach.   

Abstract

PURPOSE: Little knowledge exists about how neurotransmitters behave in the diabetic retina. In this study, the authors measured the concentration of two neuropeptides, substance P and vasoactive intestinal polypeptide, in the streptozotocin-induced diabetic rat retina in a time-dependent manner.
METHODS: The retinas of 1-, 3-, 5-, 8-, and 12-week diabetic rats were processed using a highly sensitive radioimmunoassay for both substance P and vasoactive intestinal polypeptide. Furthermore, the peptide-immunoreactivities were characterized by high-pressure liquid chromatography.
RESULTS: Substance P and vasoactive intestinal polypeptide were found to be significantly reduced with a maximum decrease of 28.6% (+/-6.7) and 64.5% (+/-10.7) after 5 weeks, respectively. The peptide-immunoreactivities were found in a major peak coeluting with the synthetic peptides indicating that the quantitative values measured by radioimmunoassay represent the authentic peptides.
CONCLUSIONS: The reduction of substance P and vasoactive intestinal polypeptide is in clear contrast to the amino acid transmitters GABA and glycine, which have been shown to be elevated in this early stage of diabetic retinopathy. This finding is important for three reasons: First, the decrease may result in reduced excitability of inner retinal neurons, as both peptides are known to modulate the excitability of these neurons; second, the decrease may be the consequence of a depressing and/or damaging effect by excitotoxins; and third, it may help explain why neovascularizations do not occur in this animal model, although VEGF is massively upregulated, as substance P is a very potent vascular growth factor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274084

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Protective effects of vasoactive intestinal peptide (VIP) in ischemic retinal degeneration.

Authors:  K Szabadfi; B Danyadi; P Kiss; A Tamas; E Fabian; R Gabriel; D Reglodi
Journal:  J Mol Neurosci       Date:  2012-04-29       Impact factor: 3.444

2.  Abnormal centrifugal axons in streptozotocin-diabetic rat retinas.

Authors:  M J Gastinger; A J Barber; S A Khin; C S McRill; T W Gardner; D W Marshak
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-10       Impact factor: 4.799

Review 3.  Neuropeptides and diabetic retinopathy.

Authors:  Robert Gábriel
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

4.  VIP protects human retinal microvascular endothelial cells against high glucose-induced increases in TNF-α and enhances RvD1.

Authors:  Haoshen Shi; Thomas W Carion; Youde Jiang; Jena J Steinle; Elizabeth A Berger
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-03-26       Impact factor: 3.072

5.  Restoring retinal neurovascular health via substance P.

Authors:  Kepeng Ou; Sonja Mertsch; Sofia Theodoropoulou; Jiahui Wu; Jian Liu; David A Copland; Stefan Schrader; Lei Liu; Andrew D Dick
Journal:  Exp Cell Res       Date:  2019-04-14       Impact factor: 3.905

Review 6.  Recent developments of neuroprotective agents for degenerative retinal disorders.

Authors:  Kepeng Ou; Youjian Li; Ling Liu; Hua Li; Katherine Cox; Jiahui Wu; Jian Liu; Andrew D Dick
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.